- Ixion Strengthens Its Oxalate-Related Intellectual Property Portfolio
-
 ALACHUA, FL-April 17, 2002- Ixion Biotechnology, Inc., the world leader in oxalate-related disease technology has been issued a new patent (US 6,355,242) relating to the treatment or prevention of oxalate-related disease in animals through the delivery of oxalate-degrading bacteria and enzymes.
- "This complements and strengthens a family of now seven oxalate-related U.S. patents that cover a broad range of therapeutic and diagnostic uses in both humans and non-humans. As Ixion prepares to advance its oxalate-degrading product into the clinic, it is reassuring to achieve a further strengthening of our oxalate-related intellectual property," stated Louis G. Kessler, Ph.D., Ixion's vice president of corporate development. Harmeet Sidhu, Ph.D., vice president and director of research of Ixion's oxalate business unit is a co-inventor of the newly issued patent with Milton J. Allison, Ph.D., of Iowa State University.
- "Ixion has dedicated itself to the development of innovative approaches to treating oxalate-related conditions in humans and companion animals. We believe that our approach has the potential of enhancing the quality of life of many who suffer from oxalate-related conditions, including primary hyperoxaluria, kidney stones, enteric hyperoxaluria, and cystic fibrosis", said Dr. Sidhu.
- Ixion's other business unit is developing an adult stem cell approach to treat insulin-dependent diabetes. Ixion has demonstrated the feasibility of using adult, somatic stem cells to produce new pancreatic stem cell preparations for the treatment of diabetes. The Company also owns, or has licensed exclusive rights to patents in diabetes. For more information about Ixion's current activities and recent news releases, visit Ixion's Web site at www.ixion-biotech.com or call 386-418-1428, Ext. 301.
- This news release discusses historical information and includes forward-looking statements that involve a number of risks and uncertainties, such as risks associated with pre-clinical and clinical development in the biotechnology industry, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments and costs of developing, producing and selling products.
- Contacts:
-
-
-
-
-
-
-
-
- Louis G. Kessler, Ph.D.
Ixion Biotechnology, Inc.
386-418-1428 (voice)
386-418-1583 (fax)
Info@ixion-biotech.com
Lisette Hilton
561-392-5649 (voice)
561-392-7496 (fax)
Info@ixion-biotech.com
-
-
-
|
